Transgene and NEC Report 100% Three-Year Disease-Free Survival With TG4050 Personalized Neoantigen Vaccine in Phase 1 Head and Neck Cancer; Nature Communications Publication
Transgene (Euronext Paris: TNG) and NEC Corporation announced Wednesday September 2, 2026 sustained 100% three-year disease-free survival with TG4050 (a personalized neoantigen vaccine using Transgene's myvac vectorized viral platform combined with NEC's AI-driven neoantigen selection) in the Phase 1 portion of a randomized Phase 1/2 trial evaluating adjuvant treatment for HPV-negative head and neck squamous cell carcinoma following surgery and chemoradiotherapy. Strong and persistent CD8+ T-cell responses against patient-specific tumor neoantigens were observed and maintained for more than one year after the last vaccination. The Phase 1 clinical and translational findings were published in Nature Communications. Next milestones: first immunological data from the Phase 2 portion expected H2 2026, and two-year efficacy data (DFS) from Phase 2 expected Q1 2028. The result extends the personalized neoantigen vaccine class case established by the Merck-Moderna intismeran (mRNA-4157) August 19 Phase 3 INTerpath-001 melanoma win, and continues to build the peptide-based cancer vaccine category outside the mRNA modality.